Notice of Extra General Meeting
Shareholders in ChronTech Pharma AB (publ) are hereby summoned to an Extra General Meeting (EGM) Thursday the 16th of May 2013, at 14.00 at Kilpatrick Townsend Lawfirm’s office, Hovslagargatan 5 B, 5 tr in Stockholm.
To participate in the EGM shareholders shall both be incorporated in the of Euroclear Sweden AB kept book of shareholders on the 10th of May 2013, and apply for participation at the EGM to the Company via mail at the address ChronTech Pharma AB, Hälsovägen 7, 141 57 Huddinge, per fax 08-449 84 81, per telephone 08-449 84 80, per e-post email@example.com, or via the Company’s home page www.chrontech.se. Application must have been received at the latest by Friday, the 10th of May 2013. Shareholders who have their shares registered with a trustee must in good time before the 10th of May 2013 have their shares temporarily have their shares registered in their own name in order to participate in the EGM.
1. Opening of the EGM
2. Election of chairman for the EGM
3. Establishment and approval of shares for voting
4. Approval of the Agenda
5. Election of one or two Protocol Adjusters
6. Inquiry of whether the EGM has been duly been summoned
7. Proposal for the sale of the Company’s hepatitis technologies
8. Closing of the EGM
Proposal for reconstruction of the Company (item 7)
The Board of Directors of ChronTech Pharma AB (”the Company”) put forward the following additional proposal as step in the reconstruction of the Company as a complement to what was decided at the EGM of the 19th of April 2013. The group of shareholders has now offered to acquire the entire, i.e. also the remainder 30% and not only approximately 70% of the Company’s project regarding development of DNA vaccines against hepatitis B and hepatitis C. The purchase consideration now also includes a deferred consideration of 1 MUSD. The proposal also includes the funding of the development of the IVIN DEVICE for use in combination with hepatitis vaccines up to US$1,500,000 on the development of the IVIN DEVICE in exchange for an exclusive license for use with hepatitis vaccines. Please see attached “term sheet”.
Shareholders representing more than 60 per cent of the shares in the Company have declared that they support the proposal for reconstruction.
The complete proposal for decision will be held accessible at the Company (address and telephone number as above) and on the Company’s home page www.chrontech.se and will be sent to those shareholders who apply for this with the Company.
Huddinge in April 2013
CHRONTECH PHARMA AB (publ)
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Mobile phone: +46 709 28 05 28
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.